Related Experiment Video
Updated: Jun 3, 2026
10:09
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
Linagliptin: in type 2 diabetes mellitus
1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Drugs
|March 30, 2011
Summary
Linagliptin, a DPP-4 inhibitor, effectively lowers blood sugar in type 2 diabetes patients. It demonstrated significant improvements in glycemic control with minimal side effects and a low risk of hypoglycemia.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology
- Diabetes Mellitus Research
Background:
- Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral antihyperglycemic agents.
- Linagliptin is a novel DPP-4 inhibitor with a pharmacokinetic profile favoring non-renal elimination.
- Inadequate glycemic control in type 2 diabetes mellitus (T2DM) necessitates effective therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and tolerability of linagliptin in adult patients with T2DM.
- To compare linagliptin's effects on glycemic control against placebo and voglibose.
- To assess linagliptin's utility as monotherapy and in combination with other oral antihyperglycemic agents.
Main Methods:
- Two double-blind, multicenter trials assessed oral linagliptin monotherapy (5 or 10 mg once daily) versus placebo in T2DM patients.
- A 26-week double-blind, multicenter trial compared linagliptin (5 or 10 mg once daily) with voglibose (0.2 mg thrice daily).
- Several trials evaluated linagliptin (5 mg once daily) as add-on therapy to metformin, sulfonylurea, or metformin plus sulfonylurea, and in combination with pioglitazone.
Main Results:
- Linagliptin monotherapy significantly improved glycemic control (HbA1c reduction of -0.69% to -0.88%) compared to placebo.
- Linagliptin demonstrated superior efficacy over voglibose in improving glycemic control.
- Add-on therapy with linagliptin resulted in clinically relevant HbA1c reductions compared to placebo plus existing therapies.
- Linagliptin exhibited a favorable safety profile with neutral or minimal impact on body weight and a low incidence of hypoglycemia.
Conclusions:
- Linagliptin is a potent and selective DPP-4 inhibitor effective in improving glycemic control in T2DM.
- Linagliptin offers a valuable therapeutic option as monotherapy or in combination with other oral antihyperglycemic agents.
- The drug is generally well-tolerated, with a low risk of hypoglycemia and minimal effect on body weight.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...